Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakiyama, Emiko, Chinen, Yoshiaki, Tsukamoto, Taku, Takimoto-Shimomura, Tomoko, Kuwahara-Ota, Saeko, Matsumura-Kimoto, Yayoi, Shimura, Yuji, Kobayashi, Tsutomu, Horiike, Shigeo, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152536/
https://www.ncbi.nlm.nih.gov/pubmed/32308443
http://dx.doi.org/10.2147/IDR.S249030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152536/
https://www.ncbi.nlm.nih.gov/pubmed/32308443
http://dx.doi.org/10.2147/IDR.S249030

Ejemplares similares